Nacubactam is under clinical development by Meiji Seika Pharma and currently in Phase I for Urinary Tract Infections. According to GlobalData, Phase I drugs for Urinary Tract Infections have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nacubactam’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nacubactam overview

Nacubactam (RG6080, RO7079901) is under development for the treatment of complicated urinary tract infections including pyelonephritis and gram-negative bacterial infections such as Pseudomonas aeruginosa infections,hospital acquired bacterial pneumonia, ventilator associated bacterial pneumonia and complicated intra-abdominal infections. The drug candidate is administered intravenously. It is a new molecular entity (NME) and a diazabicyclooctane beta-lactamase inhibitor.

Meiji Seika Pharma overview

Meiji Seika Pharma, a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider. The company is engaged in providing pharmaceutical, veterinary drugs and chemicals used for agriculture. The company offers Streptomycin Meiji, Kanamycin Meiji, Habekacin, Orapenem, Reflex, Sycrest, Depromel and others. It operates manufacturing and development technologies, which provides a series of excellent antibacterial drugs. Meiji Seika Pharma also carries out research and development programs on infectious diseases and central nervous system disorders. The company offers products for human and veterinary care. It operates research centre, laboratories, and agricultural and veterinary research laboratories in Japan. Meiji Seika Pharma is headquartered in Tokyo, Japan.

For a complete picture of Nacubactam’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.